4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.

1 Department of Pharmaceutics, Rutgers University, Piscataway, NJ, United States 2 Cancer Pharmacology Program, Cancer Institute of New Jersey, New Brunswick, NJ, United States This review article ...

To this end, MGD010, a bispecifc DART® molecule, was designed to exploit the inhibitory function of the checkpoint molecule, CD32B, (FcγRIIb) via its simultaneous co-ligation with the BCR component, ...

Here, we review the ongoing developments with CAR T cells in the field of autoimmune disorders. We will cover first clinical results of applying anti-CD19 and anti-B cell maturation antigen CAR T ...